Similar articles

• Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.

  Crowley HJ, Yaremko B, Selig WM, Janero DR, Burghardt C, Welton AF, O'Donnell M. Crowley HJ, et al. J Pharmacol Exp Ther. 1991 Oct;259(1):78-85. J Pharmacol Exp Ther. 1991. PMID: 1656030
• Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.

  Herbert JM, Bernat A, Valette G, Gigo V, Lale A, LaPlace MC, Lespy L, Savi P, Maffrand JP, Le Fur G. Herbert JM, et al. J Pharmacol Exp Ther. 1991 Oct;259(1):44-51. J Pharmacol Exp Ther. 1991. PMID: 1656029
• MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.

  Hwang SB, Lam MH, Szalkowski DM, MacIntyre DE, Bach TJ, Luell S, Meuer R, Sahoo SP, Alberts AW, Chabala JC. Hwang SB, et al. J Lipid Mediat. 1993 Jun;7(2):115-34. J Lipid Mediat. 1993. PMID: 8400114
• [Effect of analogs and antagonists of the thrombocyte-activating factor (PAF) on blood platelet aggregation].

  Lakin KM, Kulikov VI, Manevich EM, Muliar AG, Shvets VI. Lakin KM, et al. Farmakol Toksikol. 1988 Jul-Aug;51(4):113-23. Farmakol Toksikol. 1988. PMID: 2847936 Review. Russian. No abstract available.
• [Antagonists of platelet activating factor].

  Tokumura A, Tsukatani H. Tokumura A, et al. Seikagaku. 1985 Dec;57(12):1618-23. Seikagaku. 1985. PMID: 3009656 Review. Japanese. No abstract available.